Company
Lantheus
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])Pivotal-lookingRecruiting
Lantheus Medical ImagingIndustry
NCT07831824 · 408 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2029
Drug: [68Ga]-LNTH-2401 · For: Prostate Cancer
Sites: Grand Rapids, Michigan
- [18F]PI-2620 Phase 3 Histopathological StudyPivotal-lookingRecruiting
Lantheus Biosciences Ltd.Industry
NCT05641688 · 200 participants (planned) · Start Dec 1, 2022 · Primary completion Mar 2028
Drug: [18F]PI-2620 · For: Alzheimer Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Los Angeles, California · 25 sites in all
Marketed drugs (1)
Newest FDA action first.
- Neuraceq Florbetaben F-18 · 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.